Clostridium Difficile Infection : The Effects of Acid Suppression Therapy in Patients With Cancer
BACKGROUND: Clostridium difficile infection (CDI) is common among hospitalized patients and is particularly serious in patients with cancer. Acid suppression therapy, particularly that which uses proton pump inhibitors (PPIs), has been shown to place hospitalized adult patients at greater risk for CDI, but this relationship has not been proven among patients with cancer.
OBJECTIVES: This review assesses risk factors for CDI among patients with cancer, with a specific focus on acid suppression therapy using PPIs and histamine-2 receptor antagonists (H2RAs).
METHODS: A literature search was performed using four electronic databases.
FINDINGS: CDI increases morbidity and mortality in patients with cancer and interferes with their active treatment plans. PPIs and H2RAs increase the risk of developing CDI among patients with cancer, but PPIs carry a higher risk. Other risk factors include antibiotics, transplantation, and chemotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Clinical journal of oncology nursing - 23(2019), 2 vom: 01. Apr., Seite 165-171 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lan, Hannah [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acid suppression therapy |
|---|
| Anmerkungen: |
Date Completed 05.05.2020 Date Revised 05.05.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1188/19.CJON.165-171 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295038136 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295038136 | ||
| 003 | DE-627 | ||
| 005 | 20231225082804.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1188/19.CJON.165-171 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0983.xml |
| 035 | |a (DE-627)NLM295038136 | ||
| 035 | |a (NLM)30880804 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lan, Hannah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clostridium Difficile Infection |b The Effects of Acid Suppression Therapy in Patients With Cancer |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.05.2020 | ||
| 500 | |a Date Revised 05.05.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Clostridium difficile infection (CDI) is common among hospitalized patients and is particularly serious in patients with cancer. Acid suppression therapy, particularly that which uses proton pump inhibitors (PPIs), has been shown to place hospitalized adult patients at greater risk for CDI, but this relationship has not been proven among patients with cancer | ||
| 520 | |a OBJECTIVES: This review assesses risk factors for CDI among patients with cancer, with a specific focus on acid suppression therapy using PPIs and histamine-2 receptor antagonists (H2RAs) | ||
| 520 | |a METHODS: A literature search was performed using four electronic databases | ||
| 520 | |a FINDINGS: CDI increases morbidity and mortality in patients with cancer and interferes with their active treatment plans. PPIs and H2RAs increase the risk of developing CDI among patients with cancer, but PPIs carry a higher risk. Other risk factors include antibiotics, transplantation, and chemotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Clostridium difficile infection | |
| 650 | 4 | |a H2RAs | |
| 650 | 4 | |a PPIs | |
| 650 | 4 | |a acid suppression therapy | |
| 650 | 4 | |a prevention | |
| 650 | 7 | |a Proton Pump Inhibitors |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical journal of oncology nursing |d 1998 |g 23(2019), 2 vom: 01. Apr., Seite 165-171 |w (DE-627)NLM093543182 |x 1538-067X |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2019 |g number:2 |g day:01 |g month:04 |g pages:165-171 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1188/19.CJON.165-171 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2019 |e 2 |b 01 |c 04 |h 165-171 | ||